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Purpose: To determine whether levels of nerve growth factor (NGF) and hepa-
rin-binding epidermal growth factor-like growth factor (HB-EGF) can be used to 
objectively assess overactive bladder syndrome (OAB) treatment outcome and to 
evaluate the effects of fixed-dose fesoterodine on OAB symptoms. Materials 
and Methods: This study included 124 participants (62 patients with OAB and 
62 controls) in Severance Hospital between 2010 and 2012. In patients with 
OAB, 4 mg fesoterodine was administered once daily. Repeated evaluations of 
putative biomarker levels, urine creatinine (Cr) levels, and questionnaire respons-
es, including the Overactive Bladder Symptom Score (OABSS) and the Overac-
tive Bladder Questionnaire (OAB q), were performed from baseline to 16 weeks. 
Results: Urinary levels of NGF/Cr (OAB: 1.13±0.9 pg/mg; control: 0.5±0.29 pg/
mg) and HB-EGF/Cr (OAB: 8.73±6.55 pg/mg; control: 4.45±2.93 pg/mg) were 
significantly higher in subjects with OAB than in controls (p<0.001). After 16 
weeks of fixed-dose fesoterodine treatment, urinary NGF/Cr levels (baseline: 
1.13±0.08 pg/mg; 16 weeks: 0.60±0.4 pg/mg; p=0.02) and HB-EGF/Cr levels 
significantly decreased (baseline: 8.73±6.55 pg/mg; 16 weeks: 4.72±2.69 pg/mg; 
p=0.03, respectively). Both the OABSS and OAB q scores improved (p<0.001). 
However, there were no a statistically significant correlations between these uri-
nary markers and symptomatic scores. Conclusion: Urinary levels of NGF and 
HB-EGF may be potential biomarkers for evaluating outcome of OAB treatment. 
Fixed-dose fesoterodine improved OAB symptoms. Future studies are needed to 
further examine the significance of urinary NGF and HB-EGF levels as therapeu-
tic markers for OAB.
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INTRODUCTION
Overactive bladder syndrome (OAB) is highly prevalent and exhibits lower uri-
nary tract symptoms (LUTS) of frequency, nocturia, and urgency, with or without 
urgency urinary incontinence; urgency is the primary symptom defining OAB.1,2 
Painful bladder syndrome/interstitial cystitis (PBS/IC) is another prevalent urolog-
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nence within a 3-day period without previous history of di-
agnosis or treatment for OAB. OAB patients were treated 
with fixed-dose fesoterodine (4 mg, daily) for 4‒6 months. 
No one stopped or increased the quantity of medication. 
OAB patients were also classified as OAB wet (n=39) or 
OAB dry (n=23) based on their voiding record of having 
urgency urinary incontinence or not, respectively. Control 
subjects were recruited from among gynecologic patients 
who were scheduled to undergo hysterectomy or myomec-
tomy and who did not have urinary tract disease or LUTS. 
The exclusion criteria were the presence of asthma, chronic 
obstructive pulmonary disease, allergic diseases, a history 
of psychiatric disorders, urinary tract disease (infection, 
stone, cystitis, urothelial cell cancer, etc.), neurological dis-
eases, gynecologic cancers, or gynecologic inflammatory 
diseases (pelvic inflammatory disease, endometriosis, etc.).
All enrolled patients underwent urogynecologic assess-
ments by the same doctor, according to the algorithm from 
the Fourth International Consultation on Incontinence.11 
OAB patients also underwent cystoscopy and urodynamic 
measurements to evaluate uroflowmetry, detrusor overac-
tivity (DO), postvoid residual urine, and total bladder ca-
pacity. Urine samples were collected from the control pa-
tients preoperatively and 1 month postoperatively. In OAB 
patients, the urine samples were collected before treatment 
and at 1 and 4 months after treatment. Urinalysis was per-
formed at the time of urine collection to confirm the ab-
sence of pyuria or detectable bacteria. Subjective urinary, 
coital, and bowel symptoms were assessed in OAB patients 
through an interview utilizing two questionnaires, the Over-
active Bladder Symptom Score (OABSS) and Overactive 
Bladder Questionnaire (OAB q). 
To assess symptomatic changes, OAB subjects complet-
ed standardized OAB-specific questionnaires including the 
OABSS12 and the OAB q13 at baseline and 4 months after 
starting fesoterodine treatment. The OABSS evaluated four 
symptoms: daytime frequency, nighttime frequency, urgen-
cy, and urgency urinary incontinence. The overall score 
was the simple sum of the four symptom scores. The OAB 
q comprises an eight-item Symptom Bother scale and a 25-
item health-related quality of life (HRQL) scale with four 
domains (concern, coping, sleep, and social interaction). 
The primary endpoints were changes in urinary levels of 
NGF and HB-EGF in OAB patients from baseline to 4 
months after fesoterodine therapy. The secondary endpoints 
included changes in OABSS and OAB q scores at the same 
time-points. The questionnaire was self-administered; be-
ic disease characterized by urinary frequency, urgency, and 
chronic bladder pain.3 Although many studies have investi-
gated OAB and PBS/IC, its causes and mechanisms remain 
poorly understood. A high percentage of symptom overlap 
with PBS/IC has been noted for OAB, which implies a pos-
sible common pathophysiology, despite these being different 
diseases.4 Although diagnoses are made based on the evalu-
ation of a patient’s symptoms, the role of urinary biomarkers 
in assessing either OAB or PBS/IC has garnered greater in-
terest. Measurement of biomarkers in urine have been 
shown to be simple and easy to look at potential pathophysi-
ologies.5-9 In fact, previous studies have identified nerve 
growth factor (NGF) as a potential diagnostic biomarker 
for OAB and as a prognostic marker for measuring treat-
ment response in patients with PBS/IC.5-7
Three biomarkers have been identified in urine from PBS/
IC patients: epidermal growth factor (EGF), heparin-binding 
epidermal growth factor-like factor (HB-EGF), and antipro-
liferative factor (APF).8 Among these, HB-EGF is function-
ally antagonized by other factors via a mitogen-APF com-
plex, and its level significantly changes between PBS/IC 
patients with and without ulcers.9 Urinary urgency and fre-
quency are related to a defective urothelium in patients with 
PBS/IC, and HB-EGF is involved in this pathway.10 In OAB 
patients, urgency and frequency are also core symptoms.1,2 
To our knowledge, no studies have investigated the diag-
nostic role of urinary HB-EGF levels with OAB and the ef-
fect of OAB treatment on HB-EGF levels.
Therefore, this study was designed to examine whether 
urinary NGF and HB-EGF levels can be used as objective 
tools for assessing the therapeutic outcomes of antimusca-
rinic OAB treatment. We also evaluated the effects of a fes-
oterodine fixed-dosing regimen on OAB symptoms in OAB 
subjects using standardized questionnaires. 
MATERIALS AND METHODS
Between December 2010 and June 2012, 124 subjects were 
recruited from Yonsei University Severance Hospital in 
Seoul, Korea. The study was approved by the hospital’s In-
stitutional Review Board, and all patients provided informed 
consent to participate in the study. OAB was diagnosed 
based on the clinical symptoms of urgency or urgency in-
continence, and further confirmed using a 3-day voiding di-
ary. The inclusion criterion involved the patient reporting at 
least three episodes of urgency/urgency urinary inconti-
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and 1 and 4 months. p-values were adjusted using the Bon-
ferroni correction. Changes in UDS parameters were evalu-
ated by a McNemar’s test and paired t-test. Correlation anal-
ysis with Pearson’s correlation coefficient was used to assess 
associations between urinary NGF/Cr and HB-EGF/Cr. 
OABSS and OAB q scores in OAB patients were compared 
between those at baseline and those at 4 months after treat-
ment. A paired t-test was used for intra-group statistical 
analysis. Differences in urinary markers and symptomatic 
scores for intragroup were also assessed by correlation 
analysis. Data were analyzed using Statistical Analysis Sys-
tem software (version 9.2, SAS, Cary, NC, USA); all p-val-
ues <0.05 were considered statistically significant.
RESULTS
 
Mean ages were not statistically different between the OAB-
wet (60.4±11.2 years) and OAB-dry (56.4±12.3 years) 
groups; the controls were younger (52.9±8.8 years), how-
ever. Table 1 shows the initial urinary levels of NGF/Cr and 
HB-EGF/Cr in the OAB and control subjects. 
In patients with OAB, we checked the urinary levels of 
NGF, HB-EGF, NGF/Cr, and HB-EGF/Cr at baseline and 
at 1 and 4 months after beginning fesoterodine therapy. The 
control patients underwent these measurements only twice 
since equivalent values were observed at 4 months. Urinary 
levels of NGF/Cr and HB-EGF/Cr were significantly high-
er in OAB patients than in controls, at baseline [1.13±0.90 
(OAB) vs. 0.50±0.29 (Control) pg/mg; 8.73±6.53 (OAB) 
vs. 4.45±2.93 (Control) pg/mg; p<0.001 for both compari-
sons]. After continuing fesoterodine treatment for 4 months, 
urinary levels of NGF/Cr and HB-EGF/Cr significantly de-
creased in patients with OAB [0.70±0.57 (1 month), 0.60± 
0.40 (4 months), p=0.02; 5.76±4.24 (1 months), 4.72±2.69 
(4 months) pg/mg, respectively, p=0.03] (Fig. 1). In addi-
tion, higher mean urinary levels of NGF/Cr and HB-EGF/
Cr were observed in OAB wet patients than in OAB dry pa-
tients at baseline [1.26±1.07 (OAB wet), 0.91±0.44 (OAB 
dry); 9.4±7.73 (OAB wet), 7.59±3.68 (OAB dry) pg/mg, 
forehand, the interviewer thoroughly explained each ques-
tionnaire and the questions. Only questionnaires that con-
tained responses to all items were evaluated (i.e., incomplete 
questionnaires were excluded). 
Urine sample preparation
Clean-catch urine specimens were obtained from both OAB 
and control patients. Aliquots (20‒30 mL) of the samples 
were immediately put on ice and centrifuged at 3000 rpm 
for 10 min at 4°C. The supernatants were carefully collect-
ed and frozen (-80°C) until enzyme-linked immunosorbent 
assays (ELISAs) were performed. At the same time, 3-mL 
urine aliquots were used to measure urinary creatinine (Cr) 
levels.
ELISAs
Urinary NGF levels were measured using the Emax® Im-
muno Assay System (Promega, Madison, WI, USA) with an 
ELISA kit (USCN Life Science, Wuhan, Hubei, China). As-
says were performed according to the manufacturer’s in-
structions, as previously reported.5 For the HB-EGF ELISA, 
each well of a 96-well Immulon II plate (Dynatech Labora-
tories, Chantilly, VA, USA) was coated with 200 µL of urine 
at 4°C, overnight, as previously reported.14 The plates were 
blocked with 5% fetal bovine serum, and anti-HB-EGF an-
tibody (1 µg/mL) (R&D Systems, Minneapolis, MN, USA) 
was added in addition to biotinylated anti-goat IgG/avidin 
D-horseradish peroxidase. The total urinary NGF and HB-
EGF levels were further normalized to the concentration of 
urinary creatinine (NGF/Cr and HB-EGF/Cr levels).
   
Statistical analysis
Urinary NGF/Cr and HB-EGF/Cr levels were compared 
between controls and patients with OAB at different times 
following treatment. The differences in urinary NGF/Cr 
and HB-EGF/Cr levels were also compared between OAB-
dry and OAB-wet groups. A repeated measures analysis 
was performed using a linear mixed model with post hoc 
analysis of OAB patients who underwent repeated mea-
surements of NGF/Cr and HB-EGF/Cr levels at baseline 
Table 1. Putative Biomarker Levels in Patients with Overactive Bladder Syndrome and Controls at Baseline (Mean±SD)
Control (n=62) OAB (n=62) p value
Age (yr) 52.85±8.78   58.89±11.72 0.002*
Urinary NGF/Cr (pg/mg)   0.50±0.29 1.13±0.9 <0.001*
Urinary HB-EGF/Cr (pg/mg)   4.45±2.93   8.73±6.55 <0.001*
OAB, overactive bladder; NGF, nerve growth factor; HB-EGF, heparin-binding epidermal growth factor-like growth factor; Cr, creatinine. 
*p<0.05, paired t-test.
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awaken in the morning?”, “How often do you have a sudden 
desire to urinate, which is difficult to defer?”, and “How of-
ten do you leak urine because you cannot defer your sud-
den urge to urinate?” were lower than their corresponding 
pretreatment scores (p<0.001, for all comparisons) (Fig. 
2A). Thus, patients reported less urinary frequency and 
nocturia (p<0.001) after fesoterodine therapy. Urgency and 
urgency incontinence, as measured by OABSS, also de-
creased after anticholinergic treatment (p<0.001, for both 
comparisons). In addition, OAB q scores, including Symp-
tom Bother and the four HRQL subscales, improved after an-
ticholinergic treatment (p<0.001) (Fig. 2B). Mean OABSS 
and OAB q scores in patients significantly improved, where-
as correlation analyses between urinary markers and symp-
p<0.001]. Mean bladder capacity also significantly increased 
(p=0.037) in OAB patients after 4 months of fesoterodine 
treatment; DO decreased by half (Table 2). In addition, Ta-
ble 3 showed a strong correlation between urinary NGF/Cr 
and HB-EGF/Cr levels from baseline to 4 months after 
treatment.
The secondary outcomes (i.e., OABSS and OAB q scores) 
also changed from baseline to 4 months after treatment in 
the OAB group. The mean OABSS and OAB q scores 
changed significantly (p<0.001); more specifically, the post-
treatment scores for the questions, “How many times do 
you typically urinate after waking in the morning until you 
go to sleep?”, “How many times do you typically wake up 
to urinate from the time you go to sleep at night until you 
Fig. 1. Changes in the urinary levels of nerve growth factor/creatinine (NGF/Cr) and heparin-binding epidermal growth factor-like growth factor/creatinine 
(HB-EGF/Cr) in patients with overactive bladder (OAB) syndrome at baseline and 1 and 4 months after treatment and in the control patients at baseline and 1 
month after surgery (mean±SD). A post hoc analysis was used to test statistical significance (A), (B) urinary NGF/Cr and HB-EGF/Cr levels in OAB patients. 
Group 1: OAB patients, Group 2: controls. *p<0.05.  
Table 2. Changes in Parameters during a Urodynamic Study of Patients with Overactive Bladder Syndrome (n=62)
Baseline 4 months p value
Total bladder capacity, mL, mean±SD† 378.5±107.4 424.2±119.9     0.024*
Detrusor overactivity, n (%)‡ 46 (74.2) 23 (37.1)   <0.001*
Postvoid residual volume, n (%)‡ 0.85
    <5 mL 56 (90.2) 55 (88.7)
    5‒50 mL 3 (4.8) 4 (6.5)
    >50 mL 3 (4.8) 3 (4.8)
*p<0.05.
†Paired t-test.
‡McNemar’s test. 
Table 3. Significant Associations between Urinary NGF/Cr and HB-EGF/Cr in OAB Patients
Urinary NGF/Cr and HB-EGF/Cr r† 95% CI p value
Baseline 0.848 0.798, 0.925 <0.001*
1 month after treatment 0.951 0.875, 0.983 <0.001*
4 months after treatment 0.949 0.608, 0.903   0.004*
OAB, overactive bladder; NGF, nerve growth factor; HB-EGF, heparin-binding epidermal growth factor-like growth factor; CI, confidence interval. 
*p<0.05, correlation analysis.
†Pearson’s correlation coefficient. 
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HB-EGF, as an autocrine regulator of the growth of hu-
man bladder epithelial cells, has been proven to antagonize 
APF via activation of the mitogen-activated protein kinase 
pathway.9 A defective glycosaminoglycan layer and a per-
meable urothelium allow urinary potassium to depolarize 
nerves in the urothelium, detrusor, and perivesical area, 
leading to urinary urgency and frequency.10 We consider that 
this mechanism might also be related to OAB symptoms 
and have a keen interest in studying urinary HB-EGF levels 
in OAB patients because of its potential use as a biomarker; 
hence, this study evaluated HB-EGF levels adjusted to the 
Cr level. This Cr correction for urinary levels of biomarkers 
is routinely used in urine proteomics and has been consid-
ered valid for studies involving measurement of urinary 
proteins that are believed to be passively released into urine 
from the urothelium during the storage phase of micturi-
tion.17,18 In this study, we discerned that elevation of urinary 
HB-EGF against increased urinary NGF was a defense 
mechanism in bladder epithelium of patients with OAB. 
The protective urothelial barrier was disrupted with broken 
defense mechanism in PBS/IC, while the restoration path-
way worked normally in OAB. 
A previous study by Liu and Kuo,5 reported that urinary 
levels of NGF/Cr were higher in OAB wet patients than in 
OAB dry patients. We also found higher mean urinary lev-
els of NGF/Cr and HB-EGF/Cr in OAB wet patients than 
in OAB dry patients. A possible reason for these differences 
of both urinary markers between OAB dry and OAB wet is 
strongly associated with urgency symptoms and that higher 
levels of NGF/Cr and HB-EGF/Cr might impact the occur-
rence of DO. In a previous study, a higher incidence of DO 
was shown to be related to urgency incontinence in OAB 
tomatic scores in patients were not statistically meaningful; 
in detail, NGF/Cr level exhibited a weak correlation with 
the symptom bother domain included in the OAB q scale at 
baseline (r=0.355, p=0.006). HB-EGF/Cr level was also re-
lated to Q2, “How many times do you typically wake up to 
urinate from the time you fall asleep at night until you awak-
en in the morning?” in the OABSS questionnaire (r=-0.261, 
p=0.046). However, the correlation analysis between these 
urinary makers and clinical symptomatic scales was not 
statistically significant at 16 weeks (Table 4 and 5). 
DISCUSSION
This study identified specific uses for previously reported 
OAB and PBS/IC urinary biomarkers, NGF and HB-EGF, 
in patients with OAB. Urinary levels of NGF have proven to 
be a useful marker in patients with OAB; however, urinary 
HB-EGF levels in OAB patients undergoing fixed-dose fes-
oterodine treatment have not been reported.5-7 We simultane-
ously evaluated the urinary levels of both HB-EGF and 
NGF to verify their effectiveness as potential markers of uri-
nary HB-EGF. We found that urinary levels of both NGF/
Cr and HB-EGF/Cr were higher in OAB patients than in 
controls. After 4 months of anticholinergic therapy, both 
NGF/Cr and HB-EGF/Cr levels decreased to normal. A 
previous study reported that urinary NGF levels commonly 
increased in OAB and PBS/IC patients, whereas HB-EGF 
levels were decreased in patients with PBS/IC.15,16 Overall, 
our findings demonstrated that urinary levels of NGF/Cr 
and HB-EGF/Cr may be useful biomarkers for differentiat-
ing between OAB and PBS/IC. 
Fig. 2. Symptomatic changes in patients with overactive bladder (OAB) syndrome are shown at baseline and after 4 months of fesoterodine treatment. (A) 
Mean Overactive Bladder symptomatic score (OABSS) with standard deviation (SD) for the four questions. (B) Mean Overactive Bladder Questionnaire 
(OAB q) scores with SD for total health-related quality of life (HRQL), the four HRQL domains, and symptom bother. A positive score change in total HRQL and 
its domains indicates improvement; a negative score change in symptom bother indicates improvement (*p<0.001 vs. baseline).
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race/ethnicity, diet, and the specific time of urine collection. 
We controlled for those factors and the effects of different 
therapeutic regimens by adjusting for Cr concentrations and 
using only a fixed-dosing regimen. The fesoterodine dose 
was not increased in any of the subjects in this study, as the 
outcome improvements associated with escalated doses are 
controversial.21,22 Our study also employed specific stan-
dardized questionnaires to assess OAB symptoms in a well-
defined group of women. 
The limitation of this study is that patients in the OAB 
population were older than the controls. Second, we cannot 
suggest standardize measuring methods and cut-off values of 
our urinary markers. It is not yet established standards of 
measuring methods and cut-off value of various urinary 
markers in OAB patients in spite of previous studies.5,6,23 Our 
study did not verify sensitivity and specificity, because it 
compared levels of these markers between controls and 
OAB patients only. A future study with more broad-spec-
trum patients and more standard criteria for these urinary 
markers would strengthen the results.
wet but not OAB dry patients.5 We suggest that elevated 
NGF concurrently stimulates HB-EGF in relation to the 
protective mechanism of irritation. These observations indi-
cate that both NGF and HB-EGF are potential biomarkers 
that reflect the effects of fesoterodine in patients with OAB.
Our secondary outcomes were assessed to evaluate im-
provements in LUTS in OAB patients. The results present-
ed here showed that 4-mg fesoterodine treatment signifi-
cantly improves OABSS and OAB q scores, as well as the 
OAB subjects’ assessment of their bladder-related prob-
lems, symptoms bother, and their overall HRQL. However, 
the relevance between urinary markers and OAB symp-
toms was not significantly different from our expectations. 
This is the first report to describe the effects of fixed-dose 
fesoterodine on LUTS and both urinary biomarkers in pa-
tients with OAB. The obvious advantage of the use of nonin-
vasive urinary biomarkers is tempered by the increased vari-
ability that arises due to intra- and inter-individual changes in 
urine volume, pH, and other urine constituents.19,20 Urinary 
creatinine concentrations are influenced by age, gender, 
Table 4. The Correlation of Both Urinary Markers with Urinary Symptoms and Quality of Life Via Overactive Bladder Symptom 
Score (OABSS) and Overactive Bladder Questionnaire (OAB q) Scores in Patients with Overactive Bladder Syndrome after 
Antimuscarinic Treatment: NGF/Cr Level with OABSS and OAB q Scores
Scores and NGF/Cr Baseline 4 months
OABSS score 
    Q1
        r† (95% CI)   0.098 (-0.15, 0.42) -0.186 (-0.511, 0.166)
        p value 0.46 0.317
    Q2
        r† (95% CI)     -0.156 (-0.468, 0.085)  0.154 (-0.178, 0.481)
        p value 0.237 0.408
    Q3
        r† (95% CI)       0.128 (-0.137, 0.332) -0.138 (-0.487, 0.227)
        p value 0.333 0.461
    Q4
        r† (95% CI)       0.148 (-0.102, 0.366) -0.171 (-0.504, 0.212)
        p value 0.265 0.359
OAB q score
    Symptom bother 
        r† (95% CI)       0.355* (0.117, 0.560)  0.083 (-0.310, 0.433)
        p value 0.006 0.658
    Coping
        r† (95% CI)      -0.074 (-0.276, 0.156)  0.104 (-0.229, 0.422)
        p value 0.576 0.579
    Concern
        r† (95% CI)      -0.013 (-0.243, 0.236)  0.178 (-0.126, 0.480)
        p value 0.923 0.337
    Social interaction
        r† (95% CI)      -0.155 (-0.404, 0.128) -0.170 (-0.588, 0.293)
        p value 0.242 0.359
    Sleep
        r† (95% CI)      -0.001 (-0.404, 0.128)  0.018 (-0.410, 0.407)
        p value 0.242 0.921
    HRQL total score
        r† (95% CI)      -0.049 (-0.290, 0.212) -0.133 (-0.534, 0.336)
        p value 0.712 0.477
NGF, nerve growth factor; Cr, creatinine; HRQL, health-related quality of life.
*p<0.05, correlation analysis.
†Pearson’s correlation coefficient. 
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terstitial cystitis/bladder pain syndrome/painful bladder syndrome: 
2008 snapshot. Neurourol Urodyn 2009;28:274-86.
4. Rodríguez MA, Afari N, Buchwald DS; National Institute of Dia-
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5. Liu HT, Kuo HC. Urinary nerve growth factor level could be a 
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in patients with bladder outlet obstruction with overactive bladder 
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tor in the urinary bladder of the adult regulates neuronal form and 
function. J Clin Invest 1991;88:1709-15.
8. Keay SK, Zhang CO, Shoenfelt J, Erickson DR, Whitmore K, 
Warren JW, et al. Sensitivity and specificity of antiproliferative 
factor, heparin-binding epidermal growth factor-like growth fac-
In conclusion, urinary levels of NGF and HB-EGF may 
be potential biomarkers for evaluating OAB therapeutic re-
sults. Statistically significant improvements in OAB symp-
toms were seen in OAB patients after fixed-dose fesotero-
dine treatment. Although this study was limited in that we 
failed to detect a meaningful relationship between urinary 
markers and symptomatic scores, it provides useful conclu-
sions and suggestions for future study.
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